Meda's Dymista approved in UK, ready for hay fever season
This article was originally published in Scrip
Executive Summary
The UK's regulatory agency has granted marketing authorization for Meda's Dymista, a nasal formulation of fluticasone propionate and azelastine hydrochloride, for the treatment of moderate to severe seasonal and perennial allergic rhinitis.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.